SCHEMBL477109

SCHEMBL477109

Cc1cn2nc(Cl)ccc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.53
KDM4E B2RXH2 4/20 0.46
COMT P21964 1/20 0.44
DRD2 P14416 4/20 0.41
DRD4 P21917 4/20 0.41
DRD3 P35462 4/20 0.41
HTR1A P08908 3/20 0.41
ADRA1D P25100 3/20 0.41
ADRA1A P35348 3/20 0.41
ADRA1B P35368 3/20 0.41
SMN1; SMN2 Q16637 4/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
PDE10A Q9Y233 4/20 0.39
ALDH1A1 P00352 3/20 0.38
AHR P35869 3/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053018 0.84 DYRK1A (0.41) DYRK1AKDM4ECOMTDRD2DRD4
SCHEMBL756100 0.81 KDM4E (0.50) DYRK1AKDM4EDRD2DRD4DRD3
SCHEMBL3921056 0.81 DYRK1A (0.58) DYRK1AKDM4ECOMTSMN1; SMN2NPC1
SCHEMBL6623486 0.76 KDM4E (0.46) DYRK1AKDM4EDRD2DRD4DRD3
SCHEMBL19086949 0.76 KDM4E (0.46) DYRK1AKDM4EDRD2DRD4DRD3
SCHEMBL20033886 0.76 KDM4E (0.46) DYRK1AKDM4EDRD2DRD4DRD3
SCHEMBL3086869 0.76 KDM4E (0.44) DYRK1AKDM4ECOMTDRD2DRD4
SCHEMBL3357291 0.76 KDM4E (0.46) KDM4EDRD2DRD4DRD3HTR1A
SCHEMBL17232819 0.76 DYRK1A (0.53) DYRK1AKDM4ECOMTSMN1; SMN2NPC1
SCHEMBL16118521 0.76 KDM4E (0.46) DYRK1AKDM4EDRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4609731-A Process for brominating ergot alkaloids SANDOZ LTD. (CH) 1986-09-02 US claimed
US-12528810-B2 Small molecule inhibitors of DYRK/CLK and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-01-20 US disclosed
US-20260008790-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. (US) 2026-01-08 US disclosed
EP-4658655-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250353858-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-20 US disclosed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 US disclosed
CN-120025336-A LIN28 inhibitors and methods of use thereof 加利福尼亚大学董事会 2025-05-23 CN disclosed
EP-4308576-B1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-04-23 EP disclosed
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LTD (GB) 2025-04-10 US disclosed
CN-119454705-A Formulations and methods of use of RBP4 inhibitors 倍亮生物有限责任公司 2025-02-18 CN disclosed
US-7307165-B2 Process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) 2007-12-11 US disclosed
US-7307165-B2 Process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) 2007-12-11 US disclosed
US-20050171108-A1 Novel process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-08-04 US disclosed
EP-1541575-A1 NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE Sumitomo Chemical Takeda Agro Company, Limited (JP) 2005-06-15 EP disclosed
US-20050032650-A1 Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-02-10 US disclosed
EP-1466527-A1 FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME Sumitomo Chemical Takeda Agro Company, Limited (JP) 2004-10-13 EP disclosed
EP-0238070-B1 Sulfonylurea compounds, their production and herbicidal use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-12-29 EP disclosed
US-5017212-A For rice paddies TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-05-21 US disclosed
EP-0238070-A2 Sulfonylurea compounds, their production and herbicidal use Takeda Chemical Industries, Ltd. (JP) 1987-09-23 EP disclosed
US-4609731-A Process for brominating ergot alkaloids SANDOZ LTD. (CH) 1986-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008790-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM22, RBM17 DYRK1A 2789/4885KDM4E 2095/4885COMT 1436/4885
US-20050171108-A1 Novel process for producting imidazo[1,2-b]pyridazine derivative POR, CBR3, NR2C2 DYRK1A 1821/4885KDM4E 2179/4885COMT 3482/4885
US-12528810-B2 Small molecule inhibitors of DYRK/CLK and uses thereof CLK3, CLK2, CLK1 DYRK1A 18/4885KDM4E 2135/4885COMT 3851/4885
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 DYRK1A 2870/4885KDM4E 2060/4885COMT 339/4885
US-20250353858-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKK, DGKA DYRK1A 2302/4885KDM4E 2153/4885COMT 4328/4885
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CACNA1A, CACNA1E, CACNA1S DYRK1A 973/4885KDM4E 2441/4885COMT 3137/4885
US-20050032650-A1 Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same NOTUM, WEE1, DDT DYRK1A 576/4885KDM4E 683/4885COMT 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.